Clinical Cancer Research Meeting Calendar Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Malone, C.
Right arrow Articles by Dillman, R. O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Malone, C.
Right arrow Articles by Dillman, R. O.
Clinical Cancer Research Vol. 5, 417-423, February 1999
© 1999 American Association for Cancer Research


Experimental Therapeutics

Combination Interferon-{alpha}2a and 13-cis-Retinoic Acid Enhances Radiosensitization of Human Malignant Glioma Cells in Vitro1

Colin Malone, Patric M. Schiltz, Shankar K. Nayak, Michael W. Shea and Robert O. Dillman2

The Cell Biology Laboratory of the Patty and George Hoag Cancer Center, Newport Beach, California 92658

ABSTRACT

We investigated the individual and combined effects of cis-retinoic acid (CRA) and/or IFN-{alpha} (IFN) and/or radiation therapy (RT) against a human glioma cell line (American Type Culture Collection; U373MG) to evaluate the possible radiosensitization properties of these agents in vitro. Glioma cells were incubated for 24 h in 96-well plates (2 x 102 cells/well) in standard culture medium. Sets of U373 (n = 12) were exposed to CRA (3 x 106 µM), IFN (25 units/ml), CRA plus IFN, or standard culture medium. After an additional 24 h of incubation, the U373 cells were subjected to increasing radiation doses (up to 16 Gy). Glioma cells were harvested 92 h after irradiation, and cell survival curves were determined from [3H]thymidine incorporation data (over the last 24 h). The experiment was repeated for both the untreated control group and the combined CRA/IFN group. To verify the [3H]thymidine assays, a clonogenic assay was also performed. Single cell suspensions of U373 cells were plated out in six-well plates (n = 3). After chemical and RT treatment, colonies of 50 cells or more were counted, and cell survival curves were generated as fractions of nonirradiated controls. The amount of RT (in Gy) that would cause a 50% survival fraction (lethal dose 50 or LD50) was calculated from the survival curves by regression analysis. The following LD50s were obtained: The results showed that for both the [3H]thymidine incorporation assay and the clonogenic assay, the combination of IFN/CRA rendered U373 cells more susceptible to ionizing radiation than the untreated control or either single agent alone.


View this table:
[in this window]
[in a new window]
 
Table 0
 



This article has been cited by other articles:


Home page
Neuro OncolHome page
R. O. Dillman, W. M. Shea, D. F. Tai, K. Mahdavi, N. M. Barth, B. R. Kharkar, M. M. Poor, C. K. Church, and C. DePriest
Interferon-{alpha}2a and 13-cis-retinoic acid with radiation treatment for high-grade glioma
Neuro-oncol, January 1, 2001; 3(1): 35 - 41.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1999 by the American Association for Cancer Research.